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Abstract
Background: Tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral ribonucleic acid (RNA)
using reverse transcription polymerase chain reaction (RT-PCR) are pivotal to detecting current coronavirus disease
(COVID-19) and duration of detectable virus indicating potential for infectivity.
Methods: We conducted an individual participant data (IPD) systematic review of longitudinal studies of RT-PCR
test results in symptomatic SARS-CoV-2. We searched PubMed, LitCOVID, medRxiv, and COVID-19 Living Evidence
databases. We assessed risk of bias using a QUADAS-2 adaptation. Outcomes were the percentage of positive test
results by time and the duration of detectable virus, by anatomical sampling sites.
Results: Of 5078 studies screened, we included 32 studies with 1023 SARS-CoV-2 infected participants and 1619
test results, from − 6 to 66 days post-symptom onset and hospitalisation. The highest percentage virus detection
was from nasopharyngeal sampling between 0 and 4 days post-symptom onset at 89% (95% confidence interval
(CI) 83 to 93) dropping to 54% (95% CI 47 to 61) after 10 to 14 days. On average, duration of detectable virus was
longer with lower respiratory tract (LRT) sampling than upper respiratory tract (URT). Duration of faecal and
respiratory tract virus detection varied greatly within individual participants. In some participants, virus was still
detectable at 46 days post-symptom onset.
Conclusions: RT-PCR misses detection of people with SARS-CoV-2 infection; early sampling minimises false
negative diagnoses. Beyond 10 days post-symptom onset, lower RT or faecal testing may be preferred sampling
sites. The included studies are open to substantial risk of bias, so the positivity rates are probably overestimated.
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Background
Accurate testing is pivotal to controlling severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2),
otherwise known as the coronavirus disease 2019
(COVID-19).
Considerable political and medical emphasis has been
placed on rapid access to testing both to identify in-
fected individuals so as to direct appropriate therapy, ap-
propriate return to work, and to implement containment
measures to limit the spread of disease. However, suc-
cess depends heavily on test accuracy. Understanding
when in the disease course the virus is detectable is im-
portant for two purposes, firstly to understand when and
how to detect SARS-CoV-2, and secondly to understand
how long individuals are likely to remain infective posing
a risk to others.
The success of COVID-19 testing depends heavily on
the use of accurate tests at the appropriate time. Testing
for active virus infection relies predominantly on reverse
transcription polymerase chain reaction (RT-PCR),
which detects viral ribonucleic acid (RNA) that is shed
in varying amounts from different anatomical sites and
at different times during the disease course. It is increas-
ingly understood that differences in virus load impact
directly on diagnostic accuracy, notably giving rise to
negative tests in disease-positive individuals [1, 2].
Positivity is contingent upon sufficient virus being
present to trigger a positive test which may depend on
test site, sampling methods, and timing [3]. For example,
it is believed that positive nasopharyngeal RT-PCR de-
clines within a week of symptoms so that a positive test
later in the disease course is more likely from sputum,
bronchoalveolar lavage fluid, or stool [4]. Nomenclature
for anatomical site is also unclear, with a wide variety of
overlapping terms used such as “oral”, “throat”, “nasal”,
“pharyngeal”, and “nasopharyngeal”.
Because testing is pivotal to management and contain-
ment of COVID-19, we performed an individual partici-
pant data (IPD) systematic review of emerging evidence
about test accuracy by anatomical sampling site to
inform optimal sampling strategies for SARS-CoV-2. We
aimed to examine at what time points during SARS-
CoV-2 infection it is detectable at different anatomical
sites using RT-PCR-based tests.
Methods
This IPD systematic review followed the recommenda-
tions of the PRISMA-IPD checklist [5].
Eligibility
Eligible articles were any case series or longitudinal stud-
ies reporting participants with confirmed COVID-19
tested at multiple times during their infection and pro-
vided IPD for RT-PCR test results at these times. We
stipulated that test timings were linked to index dates of
time since symptom onset or time since hospital admis-
sion as well as COVID-19 diagnosis by positive RT-PCR
and/or suggestive clinical criteria, for example World
Health Organization (WHO) guidelines [6].
Search strategy and article selection
Search strings were designed and conducted subsequently
in PubMed, LitCOVID, and medRxiv by an experienced
information specialist (NR). The search end date was 24
April 2020. We additionally included references identified
by COVID-19: National Institute for Health Research
(NIHR) living map of living evidence (http://eppi.ioe.ac.
uk/COVID19_MAP/covid_map_v4.html), COVID-19 Liv-
ing Evidence (https://ispmbern.github.io/covid-19/living-
review/) with a volunteer citizen science team, “The Virus
Bashers” (Additional file 1: Table S1).
Data extraction
Data were extracted into pre-specified forms. We did
not contact authors for additional information. Study,
participant characteristics, and ROB were extracted in
Microsoft Excel (KG, JS, SG, JA, AW, SM). Data in-
cluded country, setting, date, number of participants and
IPD participants, inclusion criteria, IPD selection, par-
ticipant age, sample types, RT-PCR test type and equip-
ment, and primers. RT-PCR test results were extracted
using Microsoft Access (SM, BS, JP, ZZ, CH).
Risk of bias
We could not identify an ideal risk of bias (ROB) tool
for longitudinal studies of diagnostic tests, so we adapted
the risk of bias tool for diagnostic accuracy studies
QUADAS-2 [7] to include additional signalling questions
to cover anticipated issues. ROB signalling questions,
evaluation criteria, and domain assessment of potential
bias are reported (Additional file 1: Table S2).
Sampling method and grouping
Details of sampling sites and methods, including location
of the sampling site(s) and any sample grouping (for ex-
ample, if combined throat and nasal swabs), were ex-
tracted from full texts by a clinician (NS) with queries
referred to a second clinician (ST). If stated, details of
sampling methodology were recorded, including who
collected samples, information regarding anatomical
location (e.g. how the nasopharynx was identified), and
sample storage (Additional file 1: Table S3).
RT-PCR test result conversion to binary results
IPD RT-PCR results were extracted from each article
and converted to binary results (“positive” or “negative”).
Data from Kaplan-Meier (KM) curves were extracted
using Web digitizer [8] (Additional file 1: Table S3).
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Data analysis
Days since symptom onset and days since hospital ad-
mission were calculated from reported IPD. Data were
presented collated across 5-day time intervals for each
sample method, with longer times grouped within the
longest time interval, and 95% CI was calculated for
proportions. For comparison of duration of positive RT-
PCR from respiratory tract (RT) and faecal samples,
analysis and graphical presentation were restricted to
participants sampled by both methods. Data analysis
used STATA (14.2 StataCorp LP, Texas, USA)
(Additional file 1: Table S3).
Results
Included studies
A total of 5078 articles were identified, 116 full text arti-
cles were screened, and 32 articles were included [9–40]
(Fig. 1). Most articles were from China, in hospitalised
adult participants (Table 1). Articles reported on a total
of 1023 participants and 1619 test results.
Twenty-six (81%) articles reported data on test results
since the start of symptoms, and 23 (72%) since hospital
admission. Sixteen studies including 22% (229/1023) of
the participants reported both these time points: The
median time between symptom onset and hospitalisation
was 5 days (interquartile range (IQR) 2 to 7 days). The
median number of participants per study was 22 (IQR 9
to 56, range 5 to 232), and the median number of RT-
PCR test results per participant was 4 (IQR 2 to 9)
(Table 2).
Sampling site reporting
Articles variably specified sampling sites according to
anatomical location, or grouped more than one site for
analysis, for example as upper RT (Additional file 1:
Table S4). The most frequent sample sites were faeces
(n = 13), nasopharyngeal (n = 10), and throat (n = 9), al-
though there was a range of other sites including blood,
urine, semen, and conjunctival swabs (Table 2). Details
of sampling method were generally absent. Two studies
specified the person taking the samples. One study de-
scribed how the nasopharynx was identified and the
swab technique (length of contact time with the naso-
pharynx and twisting). Five studies specified sample stor-
age and transport details.
Sampling site positivity over time
We present RT-PCR test results for 11 different sam-
pling sites at different times during SARS-CoV-2 infec-
tion. Figures 2 and 3 show the number of positive and
negative RT-PCR results for 5-day time intervals since
symptom onset and time from hospital admission,
respectively.
The sampling sites yielding the greatest proportion of
positive tests were nasopharyngeal, throat, sputum, or fae-
ces. Insufficient data were available to evaluate saliva and
semen. Only 33% of participants who were tested with
blood samples had detectable virus (44/133; 6 articles [20,
26, 27, 31, 35, 38]), and almost no samples tested from
urine or conjunctival sampling detected virus presence.
Using nasopharyngeal sampling, 89% (147/166, 95% CI
83 to 93) RT-PCR test results were positive from 0 to 4
Fig. 1 PRISMA flowchart
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Table 1 Study characteristics of study design
Ref Author
year
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Table 1 Study characteristics of study design (Continued)
Ref Author
year
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days post-symptom onset and 81% (100/124, 95% CI 73
to 87) 0 to 4 days post-hospital admission (Figs. 2 and
3). At 10 to 14 days, the percentage of test results
positive reduced to 54% (120/222, 95% CI 47 to 61)
post-symptoms and 45% (37/82, 95% CI 34 to 57) post-
admission (Additional file 1: Figures S6 and S7).
Using throat sampling at 0 to 4 days post-
symptoms, 90% (91/101, 95% CI 83 to 95) of test
results from participants with SARS-CoV-2 were de-
tected by RT-PCR sampling, falling to 42% (58/139,
95% CI 33 to 50) at 10 to 14 days post-symptom on-
set (Fig. 2, Additional File 1: Figures S6 and S7).
Similar results were observed for time since hospital
admission, where at 0 to 4 days 80% (173/215, 95% CI
75 to 86) of result were positive, falling to 35% (55/
155, 95% CI 28 to 44) between 10 and 14 days (Fig. 3,
Additional file 1: Figures S6 and S7). Using faecal
sampling, 55% test results are positive (22/40, 95% CI
38 to 71) at 0 to 4 days post-symptom onset.
Upper and lower respiratory tract sampling
We further grouped sites into upper (URT) and lower
(LRT) respiratory tract. The rate of sample positivity re-
duced faster from URT sites compared to LRT sites
(Fig. 4a). Given that analysis across all participants is
likely to be influenced by preferential URT sampling of
participants with less severe disease, we also analysed
participants who underwent both URT and LRT
sampling. Again, URT sites on average cleared faster
(median 12 days, 95% CI 8 to 15 days) than LRT sites
(median 28 days, 95% CI 20 to not estimable; Fig. 4b);
the majority of participants clear virus from URT site
before LRT (Fig. 4c). Data based on time since hospital
admission are consistent with data for time since symp-
tom onset.
Faecal vs. respiratory tract sampling
Across participants sampled by both RT and faecal sam-
pling since hospital admission, 29% of participants were
Table 1 Study characteristics of study design (Continued)
Ref Author
year
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detected using RT sampling but not by faecal sampling
(52/177 participants, 95% CI 23 to 37%, 10 studies). The
time to RT-PCR tests becoming undetectable varied
greatly by participant, although time to undetectable
virus was similar for both sampling sites (Fig. 5), in par-
ticipants with RT-PCR test results from both RT and
faecal samples. Thirty-nine out of 89 participants (44%,
95% CI 33 to 55%) had a shorter duration of detection
in faecal samples than in RT samples.
Median time to clearance from RT was shorter in
participants based on time since hospitalisation (125
participants, p = 0.014), whilst similar in participants
since onset of symptoms (87 participants, p = 0.15)
(Additional file 1: Figures S8).
Intermittent false negative results
Many articles reported intermittent false negative RT-
PCR test results for participants within the monitoring
time span. Where participant viral loads were reported,
several different profiles were distinguished; two exam-
ples are shown in Fig. 6 [14, 15]. Intermittent false nega-
tive results were reported either where the level of virus
is close to the limit of detection, or in participants with
high viral load but for unclear reasons.
Risk of bias
The proportion of studies with high, low, or unclear
ROB for each domain is shown in Fig. 7, and ROB for
individual studies is shown in Additional file 1: Table S5.
All studies were judged at high ROB. All but one were
judged at high ROB for the participant selection domain
[17], mainly as they only included participants with con-
firmed SARS-CoV-2 infection based on at least one posi-
tive PCR test. Studies also frequently selected a subset of
the participant cohort for longitudinal RT-PCR testing,
and only results for these participants were included in
the study. Ten studies were judged at unclear ROB for
the index test domain as the schedule of testing was
based on clinician choice rather than being pre-specified
by the study or clinical guidelines, or because the sam-
ples used for PCR testing were not pre-specified. Eleven
studies were judged at high ROB for the flow and timing
domain mainly because continued testing was influenced
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participants were undetectable at URT sites 12 days after
symptom onset compared to 28 days for LRT.
We found that faecal sampling is not suitable for ini-
tial detection of disease, as up to 30% of participants de-
tected using respiratory sampling are not detected using
faecal sampling. Viral detection in faecal samples may be
useful to establish virus clearance, although as noted,
whether RT or faecal samples have longer duration of
viral detection varies between participants.
All included studies were judged at high ROB, so re-
sults of this review should be interpreted with caution.
Table 3 provides an overview of the major methodo-
logical limitations and their potential impact on study
results. A major source of bias is that all but one study
[19] restricted inclusion to participants with confirmed
SARS-CoV-2 infection based on at least one positive
RT-PCR test, meaning that the percentage of positive
RT-PCR testing is likely to be overestimated.
Lack of technical details, for example of how samples
are taken and RT-PCR tests performed, limits the applic-
ability of findings to current testing. Compared to real
life, studies were likely to use more invasive sampling
methods, use experienced staff to obtain samples, and
sample participants in hospital settings where sample
handling could be standardised. Consequently, estimates
of test performance are likely to be overestimated com-
pared to real-world clinical use and in community popu-
lation testing including self-test kits.
These limitations have important implications for how
testing strategies should be implemented and in
Fig. 2 Number of positive and negative RT-PCR test results since symptom onset. Each panel shows a separate site used in participant sampling.
Nasopharyngeal, saliva, and sputum were used where clearly reported. Throat included throat and oropharyngeal. Other URT includes samples
reported in articles as nasal, mixed nasal and throat, oral, pharyngeal, or upper respiratory tract. For pharyngeal sampling, it was not clear if this
was nasopharyngeal or oropharyngeal. Other LRT includes sampling reported as lower respiratory tract or one article including pleural fluid
sampling. Blood included serum, plasma, or blood. Faeces included stool or anal swab. Each panel shows 5-day time periods since the onset of
symptoms: 0–4 days, 5–9 days, 10–14 days, 15–19 days, 20–25 days, 26–30 days, 31–34 days, and 35 to max days. The numbers of positive RT-PCR
tests are shown as dark blue bars and dark grey bars from 0 to 14 days and 15 to 40 days, respectively, and the number of negative RT-PCR
results is shown similarly as light blue bars and light grey bars. Different colours are used before and after 15 days to indicate caution, as after 15
days testing is enriched in more severely ill participants. The total number of tests within a particular time period can be read from the x-axis
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particular how a negative RT-PCR test result should be
interpreted.
Putting the findings into context of literature
The accuracy of RT-PCR testing is limited by sampling
sites used, methods, and the need to test as soon as pos-
sible from symptom onset in order to detect the virus.
Previous studies have established that in COVID-19 in-
fection, viral loads typically peak just before symptoms
and at symptom onset [4] and estimated false negative
test results over time since exposure from upper respira-
tory tract samples [2]. To our knowledge, there has been
no prior systematic review of RT-PCR using IPD to
quantify the percentage of persons tested who are
positive and how this varies by time and sampling site.
Understanding the distribution of anatomical sites
with detectable virus is clinically relevant, especially
given independent viral replication sites in nose and
throat using distinct and separate genetic colonies [17].
Understanding of different patterns of detection and
duration of virus detection at different body sites is es-
sential when designing strategies of testing to contain
virus spread. Notably, it is unclear if detection of virus in
faeces is important in disease transmission, although fae-
cal infection was shown in SARS and MERS [41].
Strengths of study
This review uses robust systematic review methods to
synthesise published literature and identifies overall
Fig. 3 Number of positive and negative RT-PCR test results since hospital admission. Each panel shows a separate site used in participant
sampling. Nasopharyngeal, saliva, and sputum were used where clearly reported. Throat included throat and oropharyngeal. Other URT includes
samples reported in articles as nasal, mixed nasal and throat, oral, pharyngeal, or upper respiratory tract. For pharyngeal sampling, it was not clear
if this was nasopharyngeal or oropharyngeal. Other LRT includes sampling reported as lower respiratory tract or one article including pleural fluid
sampling. Blood included serum, plasma, or blood. Faeces included stool or anal swab. Each panel shows 5-day time periods since the hospital
admission: 0–4 days, 5–9 days, 10–14 days, 15–19 days, 20–25 days, 26–30 days, 31–34 days, and 35 to max days. The numbers of positive RT-PCR
tests are shown as dark blue bars and dark grey bars from 0 to 14 days and 15 to 40 days, respectively, and the number of negative RT-PCR
results is shown similarly as light blue bars and light grey bars. Different colours are used before and after 15 days to indicate caution, as after 15
days testing is enriched in more severely ill participants. The total number of tests within a particular time period can be read from the x-axis
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patterns not possible from individual articles. Using IPD,
we examined data across studies and avoided study-
level ecological biases present when using overall
study estimates. IPD regarding sample site at different
time points during infection is vital because it pro-
vides an overview of test performance impossible
from individual studies alone. Synthesised IPD can
also substantiate or reject patterns appearing within
individual studies. Within-participant paired compari-
sons of sampling sites also become possible with
sufficient data.
Limitations of study
The main limitation is the risk of bias in the included
studies. Although constraints were understandable given
the circumstances in which the studies were done, the
consequences for validity need to be highlighted. The
percentage of positive RT-PCR testing is likely to be
overestimated, because inclusion was restricted to partic-
ipants with confirmed SARS-CoV-2 infection based on
at least one positive RT-PCR test in all but one study
[19]. This means that people who had a COVID-19 in-
fection but never tested positive on at least one RT-
PCR test would not have been included. This could
arise if SARS-CoV-2 is not present at easily sampled
sites or at the time participants were tested. This
makes it impossible to determine the true false nega-
tive rate of the test—the proportion of people who
actually have SARS-CoV-2 but would receive a nega-
tive RT-PCR test result. It is possible that only half of
a b c
Fig. 4 Comparison of duration of detectable virus from upper and lower respiratory tract sampling. a Time to undetectable virus in upper and
lower respiratory tract samples. Kaplan-Meier with 95% confidence intervals and number at risk. All samples in review. b Time to undetectable
virus in upper and lower respiratory tract samples in participants who were tested with both upper and lower respiratory tract sampling. Kaplan-
Meier with 95% confidence intervals and number at risk. Restricted to participants with both sampling methods. c Time to undetectable virus in
upper and lower respiratory tract samples in participants who were tested with both upper and lower respiratory tract sampling. Scatterplot
where each dot represents a single participant, with the time to undetectable virus with both upper and lower respiratory tract sampling shown
for each participant
a b
Fig. 5 Comparison of days to undetectable virus from respiratory tract and faecal sampling. Time to undetectable virus in faecal compared to any
respiratory tract sample in participants who were tested with both sampling. Scatterplot where each dot represents a single participant, with the
time to undetectable virus with both faecal and respiratory tract sampling shown for each participant. Thirty percent of participants tested at
both sampling sites do not have detectable virus in faecal samples
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persons infected by SARS-CoV-2 may test positive, as
a community surveillance study in Italy found only
53% (80/152) persons tested RT-PCR positive in
households quarantined for 18 days with persons who
tested PCR positive [39]. The same study also identi-
fied households where no one tested RT-PCR positive,
but where there were clusters of persons with symp-
toms typical of COVID.
Poor reporting of sampling methods and sites im-
paired our ability to distinguish between and report
on variability between them. For some sampling
methods such as saliva and throat swabs, more stud-
ies are needed. There were also sparse data on sam-
pling methods that are becoming more widespread,
such as participant self-sampling [42] and short nasal
swab sampling (anterior nares/mid turbinate) [43].
Our index times may be subject to bias as symptom
onset is somewhat subjective and hospital admission
practices vary by country, pandemic stage, and hos-
pital role (i.e. healthcare vs. isolation). The results
presented do not correspond to following the same
participants across time, but the testing at clinically
relevant time snapshots reported from individual
studies, so that participants tested at later time points
are likely to have more severe disease; this does not
limit the interpretation of results in understanding
testing of participants in most clinical contexts.
Comparisons of sampling sites should be restricted to
participants tested at the relevant sites.
We have used analysis methods that do not in-
clude clustering within studies, to keep analyses
simple to understand and present, and to avoid com-
plications of fitting models where the number of
participants in each cluster varies. Ultimately, many
potentially eligible studies did not report IPD which
led to their exclusion, or only reported IPD for a
subset of participants in the study. We would wel-
come contact and data sharing with clinicians and
authors to rectify this.
Implications for policy/practice/future research
To avoid the consequences of missed infection, samples
for RT-PCR testing need to be taken as soon as symp-
toms start for detection of SARS-CoV-2 infection in
preventing ongoing transmission.
Even within 4 days of symptom onset, some partici-
pants infected with SARS-CoV-2 will receive negative
test results. Testing at later times will result in a higher
percentage of false negative tests in people with SARS-
CoV-2, particularly at upper RT sampling sites. After
10 days post-symptoms, it may be important to use
Fig. 6 Example participants with intermittent false negative results. a
An example of a participant with high viral load, but where alternate
RT-PCR test results report high viral load or undetectable virus. b A
participant where virus levels have reduced over time to a level
around the limit of viral detection, and at these low levels of virus,
intermittent negative results will occur due to differences in the
location or amount of sample
Fig. 7 Risk of bias by adapted QUADAS-2 domain. An adapted
version of QUADAS-2 for longitudinal studies was used (Additional
file 1: Table S2). For each domain, the percentage of studies by
concern for potential risk of bias is shown: low (green), unclear
(yellow), and high (red)
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Table 3 Biases and issues in interpretation
Domain Details of bias and applicability issues Impact on interpretation of study data
Participants (source
of bias)
In these studies, the reference test usually incorporates RT-PCR
(index test).
• RT-PCR testing is usually a key component of identifying
people with SARS-CoV-2 infection.
• Participants will not be detected or included in these studies
when SARS-CoV-2 is not present at easily sampled sites and
at the time that participants were available for testing.
Unclear how many and what severity of participants with
SARS-CoV-2 are not included in studies.
People who do not have a positive RT-PCR test at some point
are excluded. This could lead to overestimation of positivity.
Rates of positivity will be inflated as only people with virus




Most participants are identified or present based on respiratory
tract symptoms such as cough or respiratory distress.
Unclear how many and what severity of participants with
SARS-CoV-2 are not included in studies.
• Participants will not be detected or included in these studies
when less common symptoms or asymptomatic.
• Participants included will be biased to over-represent people
with detectable virus in respiratory tract sampling sites and at
times frequently used for testing (post symptom onset or at
admission to hospital).
Studies will inflate positivity for sampling sites that overlap
with sampling sites used in RT-PCR reference testing.
• For example, we identified 30% of participants with RT
positivity but with negative results from faecal sampling.
However, if participants had only faecal virus, would they
have been included in the studies?
Index test: RT-PCR
(applicability)
• Studies included are likely to use more invasive sampling
methods than acceptable in widespread population testing.
For example, nasopharyngeal testing is likely in many current
studies to be based on long swabs and self test kits.
Percentage of people with detectable virus may be
overestimated when testing is applied in real-world clinical
use and in population testing.
• Studies will use experienced staff to obtain samples, handle,
process, and conduct tests.
• Studies are mostly sampling participants in hospital settings
or in specialised research community testing research where
sample handling, transport, and storage have been
standardised.
• Variation in RT-PCR kits is minimised as studies are based in
few hospitals or limited to a research setting
Index test: RT-PCR
(applicability)
Sample RNA extraction methods are designed predominantly
for respiratory samples.
• RT-PCR sample preparation kits used are mostly designed for
extraction of virus from respiratory samples, not from faecal
samples. It is unclear how efficiently these kits extract virus
RNA from stool samples.
Percentage of people with virus present in faecal samples and




RT-PCR tests detect both infectious and inactive (inactive due
to immune system or dead) virus.
Percentage of people with clinically important detectable
virus may be overestimated.




Rate of virus aggregation or clearance by immune system may
affect the sampling efficiency at some sampling sites.
• Both the innate and adaptive immune system will aggregate
and clear virus particles from bodily fluids. It is not clear what
the time scale of clearance or how this influences detection
of virus at different sites and at which time points.




Reporting of sampling sites and methods is poor.
• Poor reporting may have led to less ideal grouping of
sampling in analysis.
• Some studies are likely to use a variety of nasopharyngeal
sampling methods depending on the individual participants,
but the type of sampling is typically reported at a study level
for a particular sampling site.
Percentage of people with detectable virus may be over- or
underestimated.
Flow and timing Uncertainty and inconsistencies in time of sampling Percentage of people with detectable virus may be over- or
underestimated at particular times.
• Time of symptom onset can be subjective unless based on
fever, but some participants do not have fever.
• Time of symptom onset may be different if asked of
participants in ICU setting.
• Time of hospitalisation and discharge may be affected by
function hospitalisation serves in containment of disease
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lower RT or faecal sampling. Valid estimates are essen-
tial for clinicians interpreting RT-PCR results. However,
ROB considerations suggest that the positive percentage
rates we have estimated may be optimistic, possibly con-
siderably so.
Participants can have detectable virus in different body
compartments, so virus may not be detected if samples
are only taken from a single site. Some hospitals in the
UK now routinely take RT-PCR samples from multiple
sites, such as the nose and throat. More studies are
urgently needed on evolving sampling strategies such as
self-collected samples which include saliva and short
nasal swabs. Future studies should avoid the risks of bias
we have identified by precisely reporting the anatomical
sampling sites with a detailed methodology on sample
collection. Table 4 details example studies helpful for
future study design.
Further sharing of IPD will be important, and we
would welcome contact from groups with IPD data we
can include in ongoing research.
Conclusions
RT-PCR misses detection of people with SARS-CoV-2
infection; early sampling minimises false negative diag-
noses. Beyond 10 days post-symptom onset, lower RT or
faecal testing may be preferred sampling sites. The
Table 3 Biases and issues in interpretation (Continued)
Domain Details of bias and applicability issues Impact on interpretation of study data
spread. In some studies, the hospitals were also quarantine
centres, so participants were hospitalised immediately at onset
of mild symptoms rather than restricted to patients needing
oxygen.
Flow and timing Clinical cohort within studies changes across time points. Percentage of people with detectable virus may be
overestimated at particular later time points as these
correspond to participants who were severely ill.
• Participants who have recovered from COVID-19 in most
studies are typically not tested after 2 negative tests 24 h apart.
• Many studies only test inpatients at the hospital, so the
participants sampled between 0 and 14 days typically have less




Some studies only publish IPD data for a selection of people. Available IPD data may not represent a typical spectrum of
participants in the different settings (community setting,
hospital, ICU, nursing home, prison).
Publication bias Published data is likely to be biased towards publication of
research active groups which may not represent typical real
world.
Percentage of people with detectable virus may be
overestimated.
BAL bronchoalveolar lavage, COVID-19 coronavirus disease 2019, ICU intensive care unit, IPD individual participant data, RNA ribonucleic acid, RT-PCR reverse
transcription polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
Table 4 Examples from included studies






• Contact tracing including asymptomatic
• Hospitalised patients
Population surveillance of Italian town, with PCR testing across [39]
Contact tracing [9, 30, 34]




• Multiple sampling sites per participant
• Planned schedule of sampling
• Sampling continues after negative test results
• Sampling continues after hospital discharge
Three samples per patient, multiple testing including prolonged testing
even after multiple negative results [10]
Population surveillance of Italian town over 18 days [39]
Long follow-up post-hospital [16, 35, 36]
Planned schedule of testing ([30], asymptomatic contact tracing follow-
up [36–38])
Study design: sampling Reporting of sampling methods (sample site,
staff conducting test, sample volumes, and
methods)
Most studies had very sparse reporting of sample collection methods.




Examples of plots and tables that facilitated
sharing of individual participant data
Retrospective cohort of 96 patients all tested with sputum, faeces, and
blood. Plot shows time span of positive test results, hospitalisation timing,
and disease severity for individual patients [38]
Data showing time course of illness with PCR test results [9, 31]
Data showing RT-PCR test results by patient and time point [10]
Viral load over time [15]
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included studies are open to substantial risk of bias, so
the positivity rates are probably overestimated.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12916-020-01810-8.
Additional file 1. Including additional tables and figures: search details,
QUADAS-2 adaption, anatomical sample size details, risk of bias by article,
percentage positive and negative RT-PCR results by sample for days since
symptom onset and days since hospitalisation, time to undetectable virus
in faecal and respiratory tract.
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